Deals support discovery and preclinical development of a metabolic disease and an oncology target.
Catalyst Biosciences signed two agreements with Wyeth Pharmaceuticals with potential payments of up to $100 million plus royalties. The research collaboration and license agreements support discovery and preclinical development using Catalyst’s Alterase™ therapeutics platform (engineered human proteases) directed at a target in metabolic disease and one in oncology.
Wyeth will be responsible for the clinical development, manufacturing, and marketing of products developed as a result of these collaborations. The deal includes an upfront license payments, milestone payments, R&D funding, and royalties on product sales.